BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24240975)

  • 1. Successful management of acute myeloid leukemia transformed from myelodysplastic syndromes in an elderly patient aged over 80 years old by ultralow dose decitabine combined with amifostine and autologous CIK cells.
    Yang B; Wang HT; Cai LL; Zhao Y; Chi XH; Zhu HL; Ran HH; Yang Y; Yu RL; Li SW; Lu XC
    Ann Hematol; 2014 Jul; 93(7):1233-5. PubMed ID: 24240975
    [No Abstract]   [Full Text] [Related]  

  • 2. Ultra-low-dose decitabine combined with autologous cytokine-induced killer cells for elderly patients with acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wang H; Yang B; Chi X; Cai L; Yu R; Zhu H; Tuo S; Zhang F; Wang X; Yang Y; Wu X; Li S; Lu X
    Clin Ther; 2014 Jul; 36(7):1104-11. PubMed ID: 24986484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Curative effect of decitabine combined with cytokine-induced killer cells in two elderly patients with acute myeloid leukemia].
    Chang C; Yang B; Zhang L; Zhu HL; Lu XC; Guo B; Cai LL; Han WD; Wang Y; Fan H; Li SX; Liu Y; Yang Y; Zhai B; Ran HH; Lin J; Zhang F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):62-7. PubMed ID: 23484693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous dendritic cells combined with cytokine-induced killer cells synergize low-dose chemotherapy in elderly patients with acute myeloid leukaemia.
    Dong M; Liang D; Li Y; Kong D; Kang P; Li K; Ping C; Zhang Y; Zhou X; Zhang Y; Hong L
    J Int Med Res; 2012; 40(4):1265-74. PubMed ID: 22971478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study of autologous cytokine induced killer cells combined with chemotherapy for elderly patients with acute myeloid leukemia].
    Yang Y; Yang B; Cai LL; Ran HH; Yu RL; Chi XH; Zhu HL; Li SX; Liu Y; Wang Y; Han WD; Yao SQ; Lu XC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):58-63. PubMed ID: 24598652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current treatment options for myelodysplastic syndromes].
    Nolte F; Hofmann WK
    Dtsch Med Wochenschr; 2010 Sep; 135(38):1863-9. PubMed ID: 20842606
    [No Abstract]   [Full Text] [Related]  

  • 7. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial.
    Yang B; Lu XC; Yu RL; Chi XH; Liu Y; Wang Y; Dai HR; Zhu HL; Cai LL; Han WD
    Hematol Oncol; 2012 Sep; 30(3):115-22. PubMed ID: 22972689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.
    Lübbert M; Bertz H; Rüter B; Marks R; Claus R; Wäsch R; Finke J
    Bone Marrow Transplant; 2009 Nov; 44(9):585-8. PubMed ID: 19363531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Myelodysplastic syndromes: treatment strategy up-to-date].
    Tohyama K
    Rinsho Ketsueki; 2014 Jan; 55(1):12-21. PubMed ID: 24492032
    [No Abstract]   [Full Text] [Related]  

  • 11. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
    Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical study of autologous cytokine induced killer cell infusion treating for elderly patients with myelodysplastic syndrome].
    Liu Y; Bao EN; Yang B; Lu XC; Zhu HL; Han WD; Wang Y; Dai HR; Yao SQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):787-92. PubMed ID: 21729572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
    Sill H; Zinke-Cerwenka W; Berghold A
    Bone Marrow Transplant; 2007 Apr; 39(8):509; author reply 509-10. PubMed ID: 17322936
    [No Abstract]   [Full Text] [Related]  

  • 14. [CME myelodysplasia - a frequent hematologic neoplasia in the elderly].
    Schleiffenbaum BE
    Praxis (Bern 1994); 2014 May; 103(11):617-27. PubMed ID: 24846886
    [No Abstract]   [Full Text] [Related]  

  • 15. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
    J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
    Kantarjian H; Issa JP; Rosenfeld CS; Bennett JM; Albitar M; DiPersio J; Klimek V; Slack J; de Castro C; Ravandi F; Helmer R; Shen L; Nimer SD; Leavitt R; Raza A; Saba H
    Cancer; 2006 Apr; 106(8):1794-803. PubMed ID: 16532500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.
    Schroeder T; Czibere A; Platzbecker U; Bug G; Uharek L; Luft T; Giagounidis A; Zohren F; Bruns I; Wolschke C; Rieger K; Fenk R; Germing U; Haas R; Kröger N; Kobbe G
    Leukemia; 2013 Jun; 27(6):1229-35. PubMed ID: 23314834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute myelogenous leukemia and myelodysplastic syndromes.
    Estey EH
    Semin Hematol; 1995 Apr; 32(2):132-51. PubMed ID: 7652581
    [No Abstract]   [Full Text] [Related]  

  • 20. Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly.
    Klepin HD
    Clin Geriatr Med; 2016 Feb; 32(1):155-73. PubMed ID: 26614866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.